IP Library Granted Patent US 12,480,100
Granted Patent B2
US 12,480,100 · App. 18/671,324 · Granted Nov 25, 2025

Ketoreductase polypeptides for the preparation of phenylephrine

Inventors: Oscar Alvizo (Fremont, CA); Steven J. Collier (Concord, MA); Hans-Georg Joerg Hennemann (Bedburg, DE); Seong Ho Oh (Singapore, SG); Wenjuan Zha (Singapore, SG)
Assignee: Codexis, Inc.
C12N9/0006A61K31/137C12P13/001C12Y101/01184
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,480,100
App. No.
18/671,324
Granted
Nov 25, 2025
Kind
B2
Abstract

The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.

Claims (25)

1 . An engineered polypeptide capable of converting 1-(3-hydroxyphenyl)-2-(methylamino) ethanone to (R)-phenylephrine, wherein the amino acid sequence of the polypeptide has at least 90% identity to SEQ ID NO: 2 and comprises a residue difference E145A relative to SEQ ID NO: 2.

2 . The engineered polypeptide of claim 1 , wherein the polypeptide further comprises at least one residue difference relative to SEQ ID NO: 2 selected from I11L, A64V, T76I, V95M, S96L, V99L, F147L, F147I, V148I, T152A, L153M, S159T, Y190C, Y190G, D197A, E200P, A202F, M206C, and Y249F.

3 . The engineered polypeptide of claim 1 , wherein the polypeptide is capable of stereospecifically converting 1-(3-hydroxyphenyl)-2-(methylamino) ethanone to (R)-phenylephrine in an enantiomeric excess of at least 99%.

4 . An engineered polynucleotide encoding the engineered polypeptide of claim 1 .

5 . A method for producing a compound of Formula I from a compound of Formula II:

wherein R 2 is a group selected from: —H, —Cl, —Br, —I, —F, —CH 3 , —OH, —OCH 3 , —SH, —SCH 3 , —NH 2 , —NHCH 3 , or a long chain alkyl;

wherein R 3 is a group selected from: —H, —Cl, —Br, —I, —F, —CH 3 , —OH, —OCH 3 , —SH, —SCH 3 , —S(O)CH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —OR, —SR, —NR 2 , —SO 2 NR 2 (wherein R=—H, —CH 3 , or alkyl), ethyl, propyl, isopropyl, cyclopropyl, or a long chain alkyl;

wherein R 4 is a group selected from: —H, —Cl, —Br, —I, —F, —CH 3 , —OH, —OCH 3 , —SH, —SCH 3 , —S(O)CH 3 , —SO 2 CH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , SO 2 NR 2 (wherein R=—H, —CH 3 );

wherein R 5 is a group selected from: —H, —Cl, —Br, —I, —F, —CH 3 , —OH, —OCH 3 , —SH, —SCH 3 , —S(O)CH 3 , —SO 2 CH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —OR, —SR, —NR 2 , —SO 2 NR 2 (wherein R=—H, —CH 3 , or alkyl), ethyl, propyl, isopropyl, or cyclopropyl;

wherein R 6 is a group selected from: —H, —Cl, —Br, —I, —F, —CH 3 , —OH, —SH, or —NH 2 ;

wherein R 2 and R 3 , R 3 and R 4 , or R 4 and R 5 can optionally be connected as part of a 5 or 6 membered ring;

wherein R α is a group selected from: —H, —CH 3 , ethyl, propyl, isopropyl, cyclopropyl, or a long chain alkyl; wherein R β is a group selected from: —H, —CH 3 , ethyl, propyl, isopropyl, or cyclopropyl;

wherein R α and R β can form a ring, or wherein the R α -R β unit is a carbonyl or imino functional group;

wherein R N1 and R N2 can be independently a group selected from: —H, —CH 3 , —OH, —OCH 3 , —OR, —C(O)R (wherein R=—H, —CH 3 , or alkyl), ethyl, propyl, isopropyl, cyclopropyl, long chain alkyl, carbonyl, or carboxy;

the method comprising contacting a mixture comprising the compound of Formula II with a polypeptide of claim 1 , under reaction conditions suitable to convert the compound of Formula II to the compound of Formula I.

6 . The method of claim 5 , comprising contacting a polypeptide of claim 1 with a mixture comprising a 1-(3-hydroxyphenyl)-2-(methylamino) ethanone substrate and a buffer under reaction conditions suitable to convert 1-(3-hydroxyphenyl)-2-(methylamino) ethanone to (R)-phenylephrine.

7 . The method of claim 5 , wherein the reaction conditions comprise a temperature of about 25° C. to about 35° C.

8 . The method of claim 5 , wherein the reaction conditions comprise a temperature of about 30° C.

9 . The method of claim 5 , wherein the reaction conditions comprise a pH of about 6.5 to about 7.0.

10 . The method of claim 5 , wherein the reaction conditions comprise an initial pH of about 7.0 and then adjusting the initial pH to about 6.75 after about 2 hours.

11 . The method of claim 5 , wherein the mixture comprises 50% isopropyl alcohol.

12 . The method of claim 5 , wherein the buffer is selected from 0.1 M triethanolamine and 0.05 M potassium phosphate.

13 . The method of claim 5 , wherein the mixture comprises about 0.05 g/L NADP.

14 . The method of claim 5 , wherein the reaction conditions comprise an inert atmosphere.

15 . The method of claim 5 , wherein the reaction conditions comprise a pH of about 6.75-7.0, a temperature of about 30° C., about 50% isopropyl alcohol, about 0.05 g/L NADP, about 100 g/L 1-(3-hydroxyphenyl)-2-(methylamino) ethanone, and about 0.9-1.1 g/L of the polypeptide, wherein the reaction is carried out under N 2 for about 19-24 hours.

Continuity (9)
Continuation 17731635 · Apr 28, 2022
Continuation 17085783 · Oct 30, 2020
Continuation 16778368 · Jan 31, 2020
Continuation 16437354 · Jun 11, 2019
Continuation 15812628 · Nov 14, 2017
Continuation 14755056 · Jun 30, 2015
Division 13390677
Provisional Application 61235324 · Aug 19, 2009
Related Publication 20240301366A1 · Sep 12, 2024
References Cited (156)
US 5064761A · Schneider et al. · 1991 [cited by applicant]
US 5200335A · Hummel et al. · 1993 [cited by applicant]
US 5225339A · Wong et al. · 1993 [cited by applicant]
US 5342767A · Wong et al. · 1994 [cited by applicant]
US 5385833A · Bradshaw et al. · 1995 [cited by applicant]
US 5427933A · Chen et al. · 1995 [cited by applicant]
US 5491077A · Chartrain et al. · 1996 [cited by applicant]
US 5538867A · Durliat et al. · 1996 [cited by applicant]
US 5559030A · Matsuyama et al. · 1996 [cited by applicant]
US 5618707A · Homann et al. · 1997 [cited by applicant]
US 5700670A · Yamagishi et al. · 1997 [cited by applicant]
US 5712388A · Matsumoto et al. · 1998 [cited by applicant]
US 5767115A · Rosenblum et al. · 1998 [cited by applicant]
US 5891685A · Yamagishi et al. · 1999 [cited by applicant]
US 5891703A · Van Der Laan et al. · 1999 [cited by applicant]
US 6033823A · Van Der Laan et al. · 2000 [cited by applicant]
US 6037158A · Hummel et al. · 2000 [cited by applicant]
US 6117679A · Stemmer · 2000 [cited by applicant]
US 6207822B1 · Thiruvengadam et al. · 2001 [cited by applicant]
US 6225099B1 · Hummel et al. · 2001 [cited by applicant]
US 6376246B1 · Crameri et al. · 2002 [cited by applicant]
US 6399339B1 · Wolberg et al. · 2002 [cited by applicant]
US 6413750B1 · Hummel et al. · 2002 [cited by applicant]
US 6495023B1 · Zeikus et al. · 2002 [cited by applicant]
US 6586182B1 · Patten et al. · 2003 [cited by applicant]
US 6627757B2 · Fu et al. · 2003 [cited by applicant]
US 6645746B1 · Kizaki et al. · 2003 [cited by applicant]
US 6800477B2 · Patel et al. · 2004 [cited by applicant]
US 7067675B2 · Reddy et al. · 2006 [cited by applicant]
US 7083962B2 · Kimoto et al. · 2006 [cited by applicant]
US 9102959B2 · Alvizo et al. · 2015 [cited by applicant]
US 9834758B2 · Alvizo et al. · 2017 [cited by applicant]
US 10358631B2 · Alvizo et al. · 2019 [cited by applicant]
US 10590396B2 · Alvizo et al. · 2020 [cited by applicant]
US 10870835B2 · Alvizo et al. · 2020 [cited by applicant]
US 11345898B2 · Alvizo et al. · 2022 [cited by applicant]
US 12031159B2 · Alvizo · 2024 [cited by examiner]
US 20020061564A1 · Rozzell · 2002 [cited by applicant]
US 20030054520A1 · Bommanus et al. · 2003 [cited by applicant]
US 20030068811A1 · Patel et al. · 2003 [cited by applicant]
US 20040214297A1 · Davis et al. · 2004 [cited by applicant]
US 20040265978A1 · Gupta et al. · 2004 [cited by applicant]
US 20050095619A1 · Davis et al. · 2005 [cited by applicant]
US 20050124029A1 · Van Der Laan et al. · 2005 [cited by applicant]
US 20060195947A1 · Davis et al. · 2006 [cited by applicant]
US 20060286646A1 · Patel et al. · 2006 [cited by applicant]
US 20070083055A1 · Sturmer et al. · 2007 [cited by applicant]
US 20070243594A1 · Gupta et al. · 2007 [cited by applicant]
US 20080220990A1 · Fox · 2008 [cited by applicant]
US 20080248539A1 · Giver et al. · 2008 [cited by applicant]
US 20080318295A1 · Ching et al. · 2008 [cited by applicant]
US 20090093031A1 · Liang et al. · 2009 [cited by applicant]
US 20090104671A1 · Yasohara et al. · 2009 [cited by applicant]
US 20090155863A1 · Liang et al. · 2009 [cited by applicant]
US 20090162909A1 · Campopiano et al. · 2009 [cited by applicant]
US 20090191605A1 · Liang et al. · 2009 [cited by applicant]
US 20090311762A1 · Tschentscher et al. · 2009 [cited by applicant]
US 20090312196A1 · Colbeck et al. · 2009 [cited by applicant]
US 20100062499A1 · Mundorff et al. · 2010 [cited by applicant]
US 20110171700A1 · Breuer et al. · 2011 [cited by applicant]
EP 0369691B1 · 1994 [cited by applicant]
EP 1013758A1 · 2000 [cited by applicant]
EP 1176203A1 · 2002 [cited by applicant]
EP 1179595A1 · 2002 [cited by applicant]
EP 1908845A1 · 2008 [cited by applicant]
WO WO199522625 · 1995 [cited by applicant]
WO WO199720078 · 1997 [cited by applicant]
WO WO199735966 · 1997 [cited by applicant]
WO WO199827230 · 1998 [cited by applicant]
WO WO200042651 · 2000 [cited by applicant]
WO WO2001040450A1 · 2001 [cited by applicant]
WO WO2001075767A2 · 2001 [cited by applicant]
WO WO2002086126A2 · 2002 [cited by applicant]
WO WO2005017135A1 · 2005 [cited by applicant]
WO WO2005018579A2 · 2005 [cited by applicant]
WO WO2005033094A2 · 2005 [cited by applicant]
WO WO2005054491A1 · 2005 [cited by applicant]
WO 2005077171A1 · 2005 [cited by applicant]
WO WO2007010944A1 · 2007 [cited by applicant]
WO WO2007012428A1 · 2007 [cited by applicant]
WO WO2008042876A2 · 2008 [cited by applicant]
WO WO2008103248A1 · 2008 [cited by applicant]
WO WO2009036404A2 · 2009 [cited by examiner]
WO WO2009086283A1 · 2009 [cited by applicant]
WO WO2010031776A2 · 2010 [cited by applicant]
Supplementary European Search Report dated Feb. 12, 2013. [cited by applicant]
Guo, H.H. et al., “Protein tolerance to random amino acid change,” PNAS, 101(25):9205-9210 [2004]. [cited by applicant]
Lazar, E., et al., “Transforming Growth Factor ox: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, 8(3):1247-1252 [1988]. [cited by applicant]
Hill, M.A., et al., “Functional Analysis of Conserved Histidines in ADP-Glucose Pyrophosphorylase from [cited by applicant]
Branden, C., et al., Introduction to Protein Structure, 2nd edition, Garland Science Publisher, pp. 3-12 [1999]. [cited by applicant]
Wacey, A.I., et al., “Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53,” Hum. Genet., 104:15-22 [1999]. [cited by applicant]
Genpept Accession No. WP_035452557.1 dated Dec. 23, 2014. [cited by applicant]
Genpept Accession No. WP054768785.1 dated Oct. 31, 2016. [cited by applicant]
Amidjojo et al., 2005, “Asymmetric Synthesis of Tert-butyl (3R, 5S)6-chloro-dihydroxyhexanoate with [cited by applicant]
Baerga-Ortiz et al., 2006, “Directed Mutagenesis Alters the Stereochemistry of Catalysis by Isolated Ketoreductase Domains from the Erythromycin Polyketide Synthase,” [cited by applicant]
Bisel et al., 2007, “Stereochemical clarification of the enzyme-catalysed reduction of 2-acetylchromen-4-one,” [cited by applicant]
Bradshaw et al., 1992, “ [cited by applicant]
Breyer-Pfaff et al., 1999, “High-affinity Stereoselective Reduction of the Enantiomers of Ketotifen and of Ketonic Nortriptyline Metabolites by Aldo-Keto Reductases from Human Liver,” [cited by applicant]
Cha et al., 2002, “Stereochemical control in diastereoselective reduction of α-substituted-β-ketoesters using a reductase purified from [cited by applicant]
Daussmann et al., 2006, “Oxidoreductases and Hydroxynitrilase Lyases: Complementary Enzymatic Technologies for Chiral Alcohols,” [cited by applicant]
Fuganti et al., 1993, “Microbial Generation of (2R,3S)- and (2S,3S)-Ethyl 2-Benzamidomethyl-3-hydroxybutyrate, a Key Intermediate in the Synthesis of (3S,1'R)-3-(1'-Hydroxyethyl)azetidin-2-one,” [cited by applicant]
Genbank Accession No. 1NXQ_A dated Sep. 24, 2008. [cited by applicant]
Genbank Accession No. AB036927 dated Feb. 2, 2001. [cited by applicant]
Genbank Accession No. ABJ63353.1 dated Mar. 5, 2010. [cited by applicant]
Genbank Accession No. AJ544275 dated Feb. 5, 2010. [cited by applicant]
Genbank Accession No. AAN73270 dated Nov. 3, 2003. [cited by applicant]
Genbank Accession No. AAP94029 dated Apr. 1, 2004. [cited by applicant]
Genbank Accession No. AF160799 dated Dec. 9, 1999. [cited by applicant]
Genbank Accession No. BAA24528.1 dated Jan. 28, 1998. [cited by applicant]
Genbank Accession No. CAD66648 dated Feb. 5, 2010. [cited by applicant]
Genbank Accession No. CP00046 dated Mar. 5, 2010. [cited by applicant]
Genbank Accession No. JC7338 dated Jun. 3, 2002. [cited by applicant]
Genbank Accession No. NP011476 dated May 17, 2010. [cited by applicant]
Genbank Accession No. NP010656.1 dated May 17, 2010. [cited by applicant]
Genbank Accession No. NP010159.1dated May 17, 2010. [cited by applicant]
Genbank Accession No. NP014490.1dated May 17, 2010. [cited by applicant]
Genbank Accession No. NP631415.1 dated Mar. 30, 2010. [cited by applicant]
Genbank Accession No. P41747 dated Apr. 20, 2010. [cited by applicant]
Genbank Accession No. Q07551 dated Apr. 20, 2010. [cited by applicant]
Genbank Accession No. Q9UUN9 dated Mar. 2, 2010. [cited by applicant]
Genbank Accession No. X64841.1 dated Jan. 8, 1997. [cited by applicant]
Genbank Accession No. ZP00318704.1 dated Jun. 17, 2004. [cited by applicant]
Genbank Accession No. ZP00202558.1 dated Oct. 4, 2004. [cited by applicant]
Goldberg et al., 2007, “Biocatalytic ketone reduction—a powerful tool for the production of chiral alcohols—part I: processes with isolated enzymes,” [cited by applicant]
Gröger et al., 2004, “Preparative asymmetric reduction of ketones in a biphasic medium with an (S)-alcohol dehydrogenase under in situ-cofactor-recycling with a formate dehydrogenase,” [cited by applicant]
Honig et al., 1994, “Enzymatic Resolutions of Heterocyclic Alcohols,” [cited by applicant]
Hummel et al., 1989, “Dehydrogenases for the synthesis of chiral compounds,” [cited by applicant]
Hummel, 1990, “Reduction of acetophenone to R(+)-phenylethanol by a new alcohol dehydrogenase from [cited by applicant]
Hummel, 1999, “Large-scale applications of NAD(P)-dependent oxidoreductases: recent developments,” [cited by applicant]
Jörnvall et al., 1995, “Short-chain dehydrogenase/reductases (SDR),” [cited by applicant]
Kallberg et al., 2002, “Short-chain dehydrogenase/reductase (SDR) relationships: A large family with eight clusters common to human, animal, and plant genomes,” [cited by applicant]
Kallberg et al., 2002, “Short-chain dehydrogenases/reductases (SDRs) Coenzyme-based functional assignments in completed genomes,” [cited by applicant]
Kaluzna et al., 2005, “Ketoreductases: stereoselective catalysts for the facile synthesis of chiral alcohols,” Tetrahedron: Asymmetry 16: 3682-3689. [cited by applicant]
Kataoka et al., 2003, “Novel bioreduction system for the production of chiral alcohols,” Appl Microbiol Biotechnol 62:437-445. [cited by applicant]
Nakamura et al. 2003, “Recent developments in asymmetric reduction of ketones with biocatalysts,” Tetrahedron: [cited by applicant]
Neifind et al., 2000, “Crystallization and preliminary characterization of crystals of R-alcohol dehydrogenase from lactobacillus brevis,” [cited by applicant]
Niefind et al., 2003, “The Crystal Structure of R-specific Alcohol Dehydrogenase from [cited by applicant]
Petrash et al., 2001, “Functional Genomic Studies of Aldo-keto Reductases,” [cited by applicant]
Rodrigues et al., 2004, “Recent Advances in the Biocatalytic Asymmetric Reduction of Acetophenones and α,β-Unsaturated Carbonyl Compounds,” [cited by applicant]
Santaniello et al., 1984, “Chiral Synthesis of a Component of Amanita muscaria, (-)-4-hydroxypyrrolidin-2-one, and Assessment of its Absolute Configuration,” [cited by applicant]
Schlieben et al., 2005, “Atomic Resolution Structures of R-specific Alcohol Dehydrogenase from [cited by applicant]
Stemmer et al., 1994, “DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution,” [cited by applicant]
Sulzenbacher et al., 2004, “Crystal Structure of [cited by applicant]
Temino et al., 2005, “Entrapment of the alcohol dehydrogenase from [cited by applicant]
Weckbecker et al., 2006, “Cloning, expression, and characterization of an (R)-specific alcohol dehydrogenase from [cited by applicant]
Wolberg et al., 2000, “Highly Regio- and Enantioselective Reduction of 3,5-Dioxocarboxylates,” [cited by applicant]
Wolberg, 2001, “Enzymatic Reduction of Hydrophobic beta, delta-Diketo Esters,” [cited by applicant]
Xie et al., 2006, “Asymmetric Reduction of o-Chloroacetophenone with [cited by applicant]
Zhao et al., 1999, “Molecular evolution by staggered extension process (StEP) in vitro recombination,” [cited by applicant]
Zhu et al., 2005, “Evaluation of substituent effects on activity and enantioselectivity in the enzymatic reduction of aryl ketones,” [cited by applicant]
International Search Report of the International Searching Authority of PCT/US2010/046020 mailed May 27, 2011. [cited by applicant]
Broussy et al., 2009, Enantioselective, ketoreductase-based intry into pharmaceutical building blocks: ethanol as tunable nicotinamid reductant: [cited by applicant]
Sorgedrager et al., 2008, “Asymetric carbonyl reductions with microbial ketoreductases,” [cited by applicant]
Makino et al., 2007, “Engineering the phenylacetaldehyde reductase mutant for improved substrate conversion in the presence of concentrated 2-propanol,” [cited by applicant]
Stampfer et al., 2002, “Biocatalytic asymmetric hydrogen Transfer,” [cited by applicant]
Yamada-Onodera et al., 2007, “Purification and Characterization of 2-Aminoacetophenone Reductase of Newly Isolated [cited by applicant]